Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 22, 2026 06:45 ET | Source: Magna Mining Inc.

Magna Mining Intersects 29.7% Copper Equivalent over 3.4 metres, consisting of 9.4% Copper, 2.3% Nickel, 19.8 g/t Gold and 8.8 g/t Platinum + Palladium within the R2 Footwall Zone at the Levack Mine in Sudbury, Ontario

SUDBURY, Ontario, June 22, 2026 (GLOBE NEWSWIRE) -- Magna Mining Inc. (TSXV: NICU) (OTCQX: MGMNF) (FSE: 8YD) (“Magna” or the “Company”) is pleased to provide the results of ongoing exploration and...
June 19, 2026 06:31 ET | Source: Sanofi Winthrop Industrie

Press Release: Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma
June 19, 2026 06:31 ET | Source: Sanofi Winthrop Industrie

Communiqué de presse : Sarclisa de Sanofi en formulation sous-cutanée approuvé au Japon pour les patients atteints de myélome multiple

Sarclisa de Sanofi en formulation sous-cutanée approuvé au Japon pour les patients atteints de myélome multiple
June 18, 2026 19:00 ET | Source: TermPlus

Australian Retirees Look to Leverage Retirement Capital To Generate Reliable Monthly Income - TermPlus June 2026 Two-Year Fixed-Term Account Delivers 8.00%* Per Annum

Sydney, Australia, June 18, 2026 (GLOBE NEWSWIRE) -- Australia's retiree population continues to grow. Around 4.4 million Australians are now aged 65 and over. That's about 17% of the population,...
June 18, 2026 09:01 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer

OCALA, Fla., June 18, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the final subject has received their first dose in the Phase 2...
June 18, 2026 08:30 ET | Source: MAIA Biotechnology, Inc.

MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University

Georgia’s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center; well recognized at the forefront of cancer innovation and discovery nationwide CHICAGO, June 18, 2026 (GLOBE...
June 17, 2026 19:00 ET | Source: TermPlus

New Diversified Monthly Income Strategy for SMSF Trustees June 2026 Update - TermPlus Launches High-Yield Fixed-Term Accounts

Sydney, Australia, June 17, 2026 (GLOBE NEWSWIRE) -- Australian superannuation regulations require self-managed super funds to maintain a documented investment strategy that covers asset allocation,...
June 17, 2026 08:47 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study

CAMBRIDGE, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune...
June 17, 2026 08:00 ET | Source: Elicio Therapeutics Inc.

Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer

100% confirmed complete radiographic and complete metabolic responses in three patients who progressed on ELI-002 7P treatment during the Phase 2 AMPLIFY-7P study and received nivolumab-based...
June 16, 2026 13:00 ET | Source: DelveInsight Business Research LLP

Glioblastoma Clinical Trial Landscape Expands: Over 200 Companies Advancing Next-Generation Therapies | DelveInsight

New York, USA, June 16, 2026 (GLOBE NEWSWIRE) -- Glioblastoma Clinical Trial Landscape Expands: Over 200 Companies Advancing Next-Generation Therapies | DelveInsight The glioblastoma clinical trial...